Experic and Flurry Powders Announce Strategic Collaboration
Experic, a contract development and manufacturing organization (CDMO) specializing in pharmaceutical powder handling, spray drying, and clinical manufacturing services, has announced a strategic partnership with Flurry Powders, LLC, a company recognized for its expertise in spray-dried formulations for inhaled and nasal drug delivery, with the collaboration designed to combine complementary scientific and technical capabilities in order to accelerate the development of next-generation therapies that depend on advanced particle engineering, particularly for complex drug molecules that require precise formulation and delivery mechanisms
Expanding Capabilities in Spray-Dried Drug Development
Under the terms of the collaboration, Flurry Powders will provide specialized support to Experic’s client base, including advanced spray drying, formulation development, particle engineering, and analytical services, thereby enhancing Experic’s ability to deliver high-performance solutions for pharmaceutical developers working on inhalation and nasal therapies, and by integrating Flurry’s expertise into its service offerings, Experic strengthens its position as a comprehensive partner for companies seeking to bring innovative drug products from early-stage research through clinical manufacturing and eventual commercialization
Unique GMP Spray Drying Advantage
A central differentiator of this partnership lies in Experic’s operation of the only Good Manufacturing Practice (GMP) spray dryer configured to Flurry’s proprietary PSD-1 specifications, a system that has demonstrated the ability to increase lung dose delivery by approximately 15–20 percent compared to conventional PSD-1 scale dryers, providing a measurable improvement in drug delivery efficiency and therapeutic performance, and this unique alignment between research and manufacturing infrastructure enables a seamless transition from research and development to GMP production, eliminating common challenges associated with process transfer, reducing the risk of performance variability, and significantly shortening development timelines
Accelerating Development of Complex Molecules
The collaboration opens new possibilities for the development of challenging pharmaceutical compounds, including lipophilic and waxy active pharmaceutical ingredients, poorly water-soluble molecules, and sensitive biologics that require stabilization in dry powder form, and by leveraging advanced spray drying and particle engineering techniques, Experic and Flurry can optimize the physical and chemical properties of these compounds to improve stability, bioavailability, and delivery efficiency, enabling pharmaceutical companies to overcome traditional barriers in drug formulation and expand the range of therapies that can be effectively delivered via inhalation or nasal routes
Leadership Perspectives on the Partnership
Matthew Mollan, Chief Executive Officer of Experic, highlighted that the partnership significantly expands the company’s capabilities in supporting developers of inhaled and nasal therapies, emphasizing that the integration of innovative spray-drying technologies with GMP manufacturing enables clients to reduce development risks, accelerate timelines, and bring high-performing powder-based drug products into clinical trials more efficiently, while Andreas Boeckl, Founder and CEO of Flurry Powders, noted that the alignment between Experic’s manufacturing infrastructure and Flurry’s PSD-1 system creates a seamless bridge between research and clinical production, allowing innovators to advance complex drug products with greater confidence, improved performance, and reduced uncertainty during scale-up
A Total Systems Approach to Drug Development
A key aspect of the collaboration is the implementation of a “total systems approach” to inhaled and nasal drug development, which integrates multiple stages of the product lifecycle into a cohesive and streamlined process, enabling optimization across formulation, device compatibility, and manufacturability, and this approach significantly reduces risks associated with scaling up production and navigating regulatory requirements, while ensuring that drug products are designed with both performance and manufacturability in mind from the earliest stages of development
End-to-End Integrated Development Ecosystem
Through this partnership, Experic and Flurry provide a fully integrated development ecosystem that connects critical elements of pharmaceutical product development into a single, coordinated framework, including formulation and particle engineering to optimize drug characteristics, spray drying and solid-state optimization to enhance stability and delivery, aerosol performance characterization to ensure effective drug deposition, device selection and engineering aligned with the target product profile, and clinic-ready GMP manufacturing and scale-up capabilities, creating a comprehensive solution that supports pharmaceutical developers from concept through clinical readiness and beyond
Enhancing Efficiency and Reducing Development Risk
By combining their expertise and infrastructure, Experic and Flurry enable pharmaceutical companies to streamline development processes, reduce technical and regulatory risks, and achieve faster time-to-market for inhalation and nasal drug products, while the ability to maintain consistency between research-scale and manufacturing-scale processes minimizes the likelihood of delays or failures during scale-up, ensuring that products can progress smoothly through clinical development and regulatory approval pathways, and this integrated approach is particularly valuable in an industry where efficiency, reliability, and speed are critical to success
About Experic’s Advanced CDMO Capabilities
Experic operates as a full-service CDMO and clinical trial supply organization, offering a comprehensive range of services that include process development, analytical and formulation development, clinical and commercial manufacturing, and clinical packaging and logistics, and since its establishment in 2018, the company has built a strong reputation for its expertise in handling challenging pharmaceutical powders and inhalation products, including capsule-based and low-dose dry powder therapies, while operating from state-of-the-art facilities in Cranbury, New Jersey, and Kilbeggan, Ireland, enabling it to manage global product delivery with high quality and efficiency, even for accelerated development programs
Flurry Powders’ Expertise in Advanced Formulation Science
Flurry Powders brings deep scientific expertise in formulation development and spray-drying technologies, with capabilities spanning colloidal science, aerosol physics, materials science, process engineering, and medical device integration, and its technologies have been validated through multiple late-stage and approved inhalation products, including those utilizing advanced particle engineering approaches such as porous particle systems, while its proprietary spray-drying platform delivers powders with superior aerosol performance and higher yields compared to conventional systems, enabling more effective drug delivery and improved patient outcomes
Supporting Rapid Innovation with Integrated Analytics
A distinguishing feature of Flurry’s approach is its integration of in-house analytical testing within a GMP-aligned development model, allowing for rapid iteration and optimization of formulations, ensuring high data integrity and enabling the creation of robust, IND-ready technical packages that meet regulatory standards, while also facilitating a smooth transition to full-scale GMP manufacturing, and when combined with Experic’s manufacturing capabilities, this creates a powerful platform for accelerating innovation and delivering high-quality pharmaceutical products to market
Transforming the Future of Inhalation and Nasal Therapies
The strategic collaboration between Experic and Flurry Powders represents a significant advancement in the field of inhalation and nasal drug development, as it brings together cutting-edge technologies, specialized expertise, and integrated processes to address some of the most complex challenges in pharmaceutical formulation and manufacturing, and by enabling more efficient development of advanced therapies, improving drug delivery performance, and reducing time-to-market, the partnership is poised to play a key role in shaping the future of respiratory and nasal drug delivery, ultimately benefiting patients through more effective and accessible treatment options worldwide
Source link:https://www.businesswire.com/
